Vir Biotechnology, Inc.
Vir Biotechnology, Inc. (NASDAQ: VIR) is a clinical-stage biopharmaceutical company focused on discovering and developing medicines for serious infectious diseases and cancer by leveraging deep immunological expertise and proprietary technology platforms. The company's mission centers on powering the immune system to… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Vir Biotechnology, Inc. does
In the company’s own words
Vir Biotechnology, Inc. (NASDAQ: VIR) is a clinical-stage biopharmaceutical company focused on discovering and developing medicines for serious infectious diseases and cancer by leveraging deep immunological expertise and proprietary technology platforms. The company's mission centers on powering the immune system to help patients overcome sophisticated evasion mechanisms employed by viruses and cancer cells.
Vir's clinical development pipeline is organized around two primary therapeutic areas. In infectious diseases, the company is advancing tobevibart, an engineered neutralizing monoclonal antibody targeting hepatitis B surface antigen, in combination with elebsiran, a small interfering RNA that reduces hepatitis B surface antigen expression. This combination is being evaluated in the registrational ECLIPSE clinical program for chronic hepatitis delta, a severe progressive liver disease with limited treatment options globally. The company is also developing HIV broadly neutralizing antibodies as potential long-acting treatments or functional cures in collaboration with the Gates Foundation, and has made available for external partnerships next-generation influenza, coronavirus, and antibody drug conjugate candidates.
In oncology, Vir is advancing three Phase 1 clinical-stage dual-masked T-cell engagers: VIR-5500 targeting PSMA in metastatic castration-resistant prostate cancer, VIR-5818 targeting HER2 in solid tumors, and VIR-5525 targeting EGFR in various solid tumors. The company is also developing multiple undisclosed masked T-cell engagers targeting clinically validated oncology targets.
Vir's competitive advantages rest on two core proprietary technology platforms. The dAIsY platform utilizes artificial intelligence and machine learning for antibody optimization, while the PRO-XTEN masking platform, exclusively licensed from Sanofi for oncology and infectious diseases, enables development of potentially best-in-class T-cell engagers with improved safety and efficacy profiles. The company maintains strategic partnerships including recent collaborations with Astellas for VIR-5500 development and commercialization, Norgine for tobevibart and elebsiran commercialization in Europe, Australia and New Zealand, and Brii Biosciences for development rights in Greater China. The company's website is www.vir.bio.
Company details
- Sector
- Healthcare
- Industry
- Biological Products
- Headquarters
- SAN FRANCISCO, CA
- Fiscal year end
- December
- CIK
- 1706431
- SIC
- 2836
Financial performance, year by year
Fiscal 2019–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Vir Biotechnology, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Vir Biotechnology, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Vir Biotechnology, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Vir Biotechnology, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Vir Biotechnology, Inc.'s last four quarterly filings that the numbers alone won't show?”